Two critical care guys walk into a recording studio and breakdown intensive care trials both old and new! We'll also do deep dives on specific topics important to practicing intensive care medicine and have special guests talking about their area of expertise!
Sigh-to-tidal compliance may indicate lung recruitability without proving benefit from recruitment. Observed associations between previous GLP-1 prescriptions and lower septic-shock mortality remain vulnerable to unmeasured confounding and do not establish an acute treatment effect.
The RATE trial finds alternative anticoagulation strategies during ECMO non-inferior to standard-dose heparin for a composite outcome, without establishing superiority. CESAR evaluates referral to specialist ECMO-centre care rather than the effect of ECMO alone.
TTM2 finds no survival or neurological advantage from 33°C hypothermia over normothermia with active fever treatment after cardiac arrest, while ICECAP examines cooling duration and finds no benefit from prolonging hypothermia to 48 hours.
A small single-centre ICU trial finds no significant difference in seven-day delirium-and-coma-free survival between olanzapine and low-dose dexmedetomidine; an exploratory mortality signal favouring olanzapine remains insufficient to justify routine practice change.
A phase II trial pairing higher protein delivery with early in-bed cycling found no significant functional or clinical benefit and stopped before planned recruitment. The appraisal also explains why fluid responsiveness supports a bolus only when an independent indication exists.
A biologically plausible endotoxin-removal strategy does not become established care through a favourable subgroup alone. EUPHRATES is neutral overall, while TIGRIS studies a narrower endotoxin range and relies on Bayesian borrowing, making generalisability, rapid assay access and cartridge delivery central to interpretation.
Critical-care and respiratory clinicians get an appraisal of mucoactive treatment for mechanically ventilated adults with difficult secretions. The neutral MARCH findings are considered alongside bronchoconstriction, transient hypoxaemia, ventilator liberation and selective rather than routine use, while tele-rehabilitation is linked to sedation reduction, breathing trials, mobilisation and post-ICU recovery.
Critical-care and emergency teams get a focused appraisal of fluid-prioritised and vasopressor-prioritised resuscitation after initial crystalloid in septic shock. ARISE-FLUIDS, CLOVERS and CLASSIC support individualised care with repeated reassessment, while VICTORY provides no support for routine high-dose intravenous vitamin C in severe burns and raises concern about possible harm.
Critical-care, emergency and nephrology clinicians get a trial-appraisal update on sodium bicarbonate in in-hospital cardiac arrest, metabolic acidosis, shock and kidney outcomes. Routine bicarbonate after in-hospital arrest shows no clear ROSC, survival or neurological benefit, while selected critically ill patients with acidosis and shock may have a renal-outcome signal.
Critical-care teams reviewing new conference results get a cautious appraisal frame across oseltamivir for severe influenza, balanced crystalloids in septic shock and volatile ICU sedation. It links trial design, baseline imbalance, biological plausibility, full publication and local capability to protocol decisions.
.svg)